Home › Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations

Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations

Jun 20, 2018
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Early clinical trial data on Merck KGaA's c-Met inhibitor tepotinib suggests the drug may be efficacious against lung and liver tumors driven by alterations in the MET oncogene.

The development program for the drug in a molecularly defined non-small cell lung cancer subpopulation includes a companion diagnostic strategy involving tests that can gauge MET exon-14-skipping mutations in tumor tissue and blood.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
02
Featured Webinar

Utilization of Multiple Molecular Testing Methodologies to Aid in Lung Cancer Patient Management

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Featured Webinar

Personalization of Oncology Pathways: Clinical Quality Initiatives Amid a Complex Molecular Landscape

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Premaitha Licenses NIPT Tech From Illumina Under Settlement

  2. Cepheid Fingerstick HCV Test Receives CE-IVD Clearance

  3. Noridian Issues Draft LCD for GenomeDx Prostate Biopsy Genomic Classifier

  4. Qiagen, NeuMoDx Ink Partnership, Merger Agreement

  5. India's MolBio Brings Tuberculosis MDx to Point of Care With Help From FIND

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.